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background:  Advanced age is a highly prevalent and arguably, the strongest risk factor for CVD. Though elderly patients derive benefits 
from LDL-C reduction, clinicians remain wary about aggressive lipid lowering in this group. Evolocumab (AMG 145), a fully human 
monoclonal antibody to PCSK9, has demonstrated effective and safe reductions in LDL-C across variable patient populations. To assess 
evolocumab efficacy and safety in elderly patients, we analyzed data for patients ≥65 and ≥75 years (y) old from a pooled analysis of phase 
2, 3, and open label studies.
Methods:  Patients ≥65 (n=1779) and ≥75 (n=223) y old were enrolled in phase 2 and 3 studies of evolocumab. Efficacy results were 
pooled from 4 phase 3 studies (n=958) and reported for the mean of weeks 10 and 12. Safety analysis included data from the phase 2 and 
phase 3 studies and their open label extension studies (n=1779, including 1301 patients from a 1-y standard of care-controlled phase).
Results:  Evolocumab significantly reduced LDL-C relative to placebo or ezetimibe, in patients ≥65 y old (Table). Similar efficacy was 
observed when analyzing only those patients ≥75 y old. Most AEs were mild and no notable imbalances were observed between control 
and evolocumab in either age group (total exposure 1758 patient-y [≥65] and 193 patient-y [≥75]), including no differences in myalgia or 
neurocognitive events.
conclusion:  PCSK9 inhibition with evolocumab potently reduced LDL-C in patients ≥65 or ≥75 y old with a side effect profile similar to 
placebo.
Table. Efficacy and Safety Results
Efficacy
Placebo-Controlled Studies Ezetimibe-Controlled Studies
Q2W QM Q2W QM
Percentage change from baseline in LDL-C at the mean of weeks 10 and 12*, n, % (SE)
Age ≥ 65 years
Evolocumab (140 mg Q2W or
420 mg QM)
n=224,
-62.9 (1.0)
n=246,
-62.5 (1.3)
n=140,
-60.4 (1.3)
n=145,
-58.4 (1.5)
Control (placebo or ezetimibe) n=114,3.2 (1.9)
n=116,
2.1 (1.8)
n=84,
-21.3 (2.1)
n=69,
-23.2 (1.8)
Age ≥ 75 years
Evolocumab (140 mg Q2W or
420 mg QM)
n=29,
-68.6 (2.2)
n=30,
-63.7 (2.2)
n=12,
-63.3 (3.0)
n=33,
-59.9 (2.2)
Control (placebo or ezetimibe) n=19,1.4 (3.6)
n=18,
0.2 (5.9)
n=7,
-24.4 (3.1)
n=5,
-16.4 (5.6)
Safety†
Parent Studies
Any Placebo Any Control
Evolocumab 
140 mg Q2W or 
420 mg QM
Any Evolocumab
Age ≥ 65 years, n 412 586 966 1193
Any adverse events, n (%) 194 (47.1) 282 (48.1) 487 (50.4) 619 (51.9)
Grade ≥3 15 (3.6) 18 (3.1) 41 (4.2) 49 (4.1)
Cardiovascular events‡ 2 (0.5) 3 (0.5) 7 (0.7) 7 (0.6)
Age ≥ 75 years, n 52 65 130 158
Any adverse events, n (%) 21 (40.4) 30 (46.2) 56 (43.1) 69 (43.7)
Grade ≥3 2 (3.8) 2 (3.1) 5 (3.8) 7 (4.4)
Cardiovascular events‡ 0 (0.0) 0 (0.0) 1 (0.8) 1 (0.6)
Extension Studies
Control in Parent Study Evolocumab in Parent Study
SoC Evolocumab + SoC SoC Evolocumab + SoC
Age ≥ 65 years, n 147 271 302 581
Any adverse events, n (%) 91 (61.9) 175 (64.6) 169 (56.0) 368 (63.3)
Grade ≥3 9 (6.1) 15 (5.5) 25 (8.3) 50 (8.6)
Cardiovascular events‡ 3 (2.0) 1 (0.4) 8 (2.6) 9 (1.5)
Age ≥ 75 years, n 24 23 34 82
Any adverse events, n (%) 16 (66.7) 17 (73.9) 20 (58.8) 52 (63.4)
Grade ≥3 3 (12.5) 6 (26.1) 4 (11.8) 9 (11.0)
Cardiovascular events‡ 1 (4.2) 1 (4.3) 2 (5.9) 2 (2.4)
*When the calculated LDL-C was <40 mg/dL, or triglycerides were > 400 mg/dL, calculated LDL-C was replaced with ultracentrifugation LDL-C from the same blood sample, if available.
†Safety analysis included data from the phase 2 and phase 3 parent studies and their open-label extension studies.
‡Positively adjudicated
SoC, standard of care; Q2W, every 2 weeks; QM, monthly
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